Industry

RADNOR, Pa.–(BUSINESS WIRE)–$MRNS #MarinusPharma—Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following investor and medical conferences in May and June: Citi Biotech Virtual Co-Panel Day May 18 at 3:30 p.m. ET. This presentation will be closed … [Read more…]

Novel Proenzyme Pharmaceutical Formulation to be Administered by Intravenous (I.V.) Injection in World First, Phase I First-In-Human Study in Advanced Cancer Patients MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company is undertaking … [Read more…]

CLEVELAND–(BUSINESS WIRE)–#JOEI_TheJournal–A recent history of arthroscopy by Dr. James S. Williams, Jr., and Dr. Asheesh Gupta reports that while there have been numerous incremental advances in arthroscopic camera technology over the last half-century, the current systems remain largely unchanged. Surgeons are tethered to the surgical tower by a power cable and by a light cord … [Read more…]

Post-Hoc Analysis Using Computer Automated Grading Indicated that Reproxalap is Statistically Superior to Vehicle (p=0.020) in Reducing Dry-Eye Associated Ocular Redness, the Primary Endpoint of Phase 3 TRANQUILITY Trial Statistical Superiority of Reproxalap over Vehicle (p=0.003) for the Primary Endpoint of Ocular Redness in the Previously Announced Phase 2 Dry Eye Chamber Trial Confirmed Using … [Read more…]

LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced management’s participation in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 in Miami Beach, Florida. H.C. Wainwright Global Investment Conference Format and Dates: Hybrid, May 23-26, 2022 Location: Fountainebleau Miami Beach … [Read more…]

TORONTO–(BUSINESS WIRE)–(TSX: LWRK) LifeWorks Inc. (the “Company” or “LifeWorks”) announced today a cash dividend of $0.065 per share for the month of May 2022, to be paid on June 15, 2022 to holders of record of shares of LWRK on May 31, 2022. LifeWorks designates this dividend to be an “eligible dividend” pursuant to subsection … [Read more…]

CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)–Anji Pharma, an emerging global medicines company, today announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. The trial is being conducted in five clinical sites in the U.S. and 20 clinical sites … [Read more…]

First non-antibiotic macrolide to go into clinical development – targeting COPD Safety, tolerability and pharmacokinetic endpoints met Phase II planning underway REYKJAVIK, Iceland–(BUSINESS WIRE)–EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects. EP395, is … [Read more…]

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference, … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, today announced that it will present updated data from the dose escalation phase of its ongoing Phase 1 trial of BCA101, a bifunctional antibody designed to target the TGF-β trap to … [Read more…]